Treatment of the benign bone tumors including femoral neck lesion using compression hip screw and synthetic bone graft

Tomoki Nakamura*, Akihiko Matsumine, Kunihiro Asanuma, Takao Matsubara, and Akihiro Sudo
Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan

Received 27 February 2015, Accepted 22 April 2015, Published online 26 June 2015

Abstract – Purpose: The proximal femur is one of the most common locations for benign bone tumors and tumor like conditions. We describe the clinical outcomes of the surgical treatment of benign lesions of the proximal femur including femoral neck using compression hip screw and synthetic bone graft.

Methods: Thirteen patients with benign bone tumors or tumor like conditions of the proximal femur including femoral neck were surgically treated. Their average age at the time of presentation was 35 years and the average follow-up time was 76 months.

Results: The average intraoperative blood loss was 1088 mL and intraoperative blood transfusion was required in eight patients. The average operative time was 167 minutes. All patients required one week and 12 weeks after surgery before full weight-bearing was allowed. All patients had regained full physical function without pain by the final follow-up. No patient sustained a pathological fracture of the femur following the procedure. All patients achieved partial or complete radiographic consolidation of the lesion within one year except one patient who developed a local tumor recurrence in 11 months. Post-operative superficial wound infection was observed in one patient, which resolved with intravenous antibiotics. Chronic hip pain was observed in one patient due to the irritation of tensor fascia lata muscle by the tube plate.

Conclusion: We suggest that the treatment of benign bone lesion of the proximal femur using compression hip screw and synthetic bone graft is a safe and effective method.

Key words: Benign bone tumor, Proximal femur, Treatment, Reinforcement.

Introduction

The proximal femur is one of the most common locations for benign bone tumors and tumor like conditions [1]. Surgical treatment may be required in patients with pathological fractures or aggressive benign tumors, such as giant cell tumor. Symptomatic patients complaining of recurrent pain or showing abnormal gait patterns due to bone tumors are also considered for surgical treatment. There are several treatment options for benign bone tumors of the proximal femur: curettage and bone grafting with or without internal fixation [1–5]. We describe the clinical outcomes of the surgical treatment of benign lesions of the proximal femur including the femoral neck using a compression hip screw and synthetic bone graft. The advantage of this method is that it offers immediate structural support and rapid graft incorporation and remodeling.

Patients and methods

Sixteen patients with primary benign bone tumors or tumor like conditions of the proximal femur including the femoral neck were surgically treated at our hospital between 2002 and 2010 (Table 1). Three lesions were treated with curettage followed by implantation of calcium phosphate cement (CPC) (BIOPEX-R®, HOYA Technosurgical Corporation, Tokyo, Japan). Reinforcement using a compression hip screw was not performed in those three cases because one tumor included a large part of femoral head and two tumors occupied less than 50% of the diameter of the femoral neck [3, 6]. Therefore, the remaining 13 patients were analyzed. There were 10 males and three females. Their average age at the time of presentation was 35 years (21–68) and the average follow-up time was 76 months (24–157). The pathological diagnosis was fibrous dysplasia in seven patients, simple bone cyst in three, giant cell tumor in two, and chondroblastoma in one. The indications for surgical treatment were the following: tumors with impending pathological fracture, tumors causing repeated pain,
and tumors with a putative expansive natural course. The 13 patients were treated with the curettage followed by implantation of CPC and/or calcium hydroxyapatite ceramic (CHA) granules (BONECERAM®; Olympus Corporation, Tokyo, Japan) in combination with reinforcement using a compression hip screw. These synthetic bone substitutes could be selected depending on the size of cavity. Additionally, CHA was applied to the tumors which had a risk of leaking outside of bone if CPC was injected.

Surgical procedure (Figures 1 and 2)

The operation was performed under general anesthesia with the patient either in the lateral or supine position on a radiolucent table. A lateral skin incision was made from the middle of the greater trochanter as far distally as necessary. A cortical window was made through the lateral femoral cortex under radiological control using a high-speed burr. Through a cortical window, a biopsy sample was obtained for frozen section. The definitive surgical procedure was done after pathological diagnosis of the frozen section. If the preoperative radiographic diagnosis did not correspond with the pathological diagnosis of the frozen section, a staged surgery was done. The window of the cortical bone must be large enough to allow adequate curettage of the tumor until underlying normal bone is exposed. A high-speed burr was used to remove the septum of the cavity after curettage of the bone tumor. After the lateral cortex and femoral head were reamed along with a guide wire which was inserted under radiological control, a compression hip screw was inserted. The synthetic bone was implanted in the bone defect. The weight-bearing was allowed from 1 week to 12 weeks depending on the initial strength of fixation and radiographic consolidation of the bone defect filled with CPC/CHA.

Results (Table 2)

The average intraoperative blood loss was 1088 mL (44–3200) and intraoperative blood transfusion was required in eight patients (62%; autologous blood transfusion in five, blood component transfusion in three). The average operative time was 167 minutes (65–255). All patients were required between 1 week and 12 weeks after surgery before full weight-bearing was allowed. There was no significant difference in the duration of restriction of full weight-bearing between the patients who were treated with CPC and CHA ($p = 0.51$, Mann-Whitney U test). All patients had regained full physical function without pain by the final follow-up. None of the patients showed pain at the operation site at the time of review. No toxicity was detected in routine blood tests. No patient sustained a pathological fracture of the femur following the procedure. All achieved partial or complete radiographic consolidation of the lesion within 1 year except one patient who developed local tumor recurrence of GCT 11 months after surgery.

Complications

Post-operative superficial wound infection was observed in one patient, which resolved with intravenous antibiotics.
Chronic hip pain was observed in one patient due to the irritation for tensor fascia lata muscle by the tube plate. She needed the removal of compression hip screw seven years after primary surgery. Although the side plate was easily removed, the lag screw could not be removed because of the rigid fixation between lag screw, bone, and CHA. After one and half years, chronic hip pain did not recur.

Discussion

We have shown clinical outcomes of the treatment procedure for the proximal femoral benign bone tumor using a compression hip screw and synthetic bone graft. Some authors recommended surgical reinforcement of the proximal femur after resection of bone tumor to prevent postoperative fracture when the tumor affects more than 50% of the diameter of the femoral neck or affects at least 50% of the bone cortex of the femoral neck [3, 6]. Therefore, we used these criteria to decide the indication of compression hip screw. Shih et al. [1] reported the results of 35 patients with benign bone tumors of the femoral neck or greater trochanter area, where the bone defect was reconstructed with allogeneic cortical strut, autologous cancellous bone graft and compression hip screw via lateral approach. They showed no postoperative tumor recurrence and no complications in any patient. We used synthetic bone graft instead of allogeneic strut because allograft has a potential for transmission of infectious disease [7–9]. Furthermore, there is no available supply of allogeneic bone in Japan.

George et al. [2] reported the results of treatment for 17 benign lesions of the proximal femur with non-vascularized autologous fibular strut grafts via lateral approach. They reported that there was postoperative tumor recurrence in two patients and no postoperative pathological fracture in

Table 2. Clinical outcome in 13 patients.

| Case | Bleeding (ml) | Operative time (min) | Implantation | Reinforcement | Time to FWB | Event | Follow-up (months) |
|------|---------------|---------------------|--------------|---------------|-----------|-------|-------------------|
| 1    | 781           | 158                 | CHA          | CHS           | 8 weeks   | Removal of CHS   | 81    |
| 2    | 1600          | 255                 | CHA          | CHS           | 3 weeks   |                   | 60    |
| 3    | 580           | 127                 | CPC          | CHS           | 1 week    |                   | 42    |
| 4    | 3200          | 170                 | CHA          | CHS           | 12 weeks  | Local recurrence | 77    |
| 5    | 218           | 135                 | CPC          | CHS           | 8 weeks   |                   | 129   |
| 6    | 1622          | 160                 | CHA/CPC      | CHS           | 4 weeks   | s/c infection    | 69    |
| 7    | 2700          | 158                 | CHA          | CHS           | 2 weeks   |                   | 73    |
| 8    | 444           | 234                 | CPC          | CHS           | 2 weeks   |                   | 107   |
| 9    | 988           | 165                 | CPC          | CHS           | 1 week    |                   | 40    |
| 10   | 600           | 200                 | CPC          | CHS           | 4 weeks   |                   | 24    |
| 11   | 1183          | 157                 | CPC          | CHS           | 1 week    |                   | 99    |
| 12   | 180           | 125                 | CHA/CPC      | CHS           | 4 weeks   | Removal of CHS   | 157   |
| 13   | 44            | 129                 | CHA          | CHS           | 1 week    |                   | 33    |

CHA, Calcium hydroxyapatite ceramic; CPC, Calcium phosphate cement; CHS, Compression hip screw; s/c, subcutaneous; FWB, Full weight-bearing.

Figure 2. Radiograph showing fibrous dysplasia of the left proximal femur (a) (21-year-old female, Case 1). This patient with fibrous dysplasia was treated in combination with curettage of the bone tumor, the reinforcement using compression hip screw and implantation of CHA into the bone defect (b, c).
any patients. Although autologous bone graft has been considered to be the ideal bone substitute, its disadvantages include limited availability, the risk of tumor implantation into the donor site, and the adverse effects at the donor site such as nerve injury, bleeding, fracture and infection.

Calcium hydroxyapatite ceramic (CHA) has been used in the orthopedic field [10] during the last two decades in Japan. Immediately after surgery, there is no difference in mechanical strength between bone filled with bone substitute and bone left empty. However, because bone substitute can act as a scaffold for new bone formation, bone filled with substitute can gradually become stronger against mechanical stress than a bone defect which is left empty. Calcium phosphate cement (CPC) is an injectable biocompatible bone substitute that has been used for various applications in orthopedic surgery, thanks to attractive mixing, handling, and biological properties. CPC offered a useful bone substitute for the treatment of bone and soft tissue tumors [11]. The compressive strength of the cured materials is about 65 MPa by 3 days after mixing, reaching a final strength of >70 MPa by 1 week after mixing [12, 13]. These synthetic bone substitutes could be selected depending on the size of cavity. Therefore, we believe that full weight-bearing could be allowed within a few weeks in patients who were treated with CPC in combination with compression hip screw, even if there is large cavity at the trochanteric and femoral neck lesions after insertion of lag screw. In ten (78%) out of 13 patients with a compression hip screw, full weight-bearing was allowed within 4 weeks and there was no postoperative fracture. This duration of restriction of weight-bearing in our cases was shorter than that in previous reports (Shih et al. [1], six weeks; George et al. [2], 14 weeks).

In conclusion, we suggest that the treatment of benign bone lesion of the proximal femur using compression hip screw and synthetic bone graft is a safe and effective method.

Conflict of interest

There was no conflict of interest in this study.

References

1. Shih HN, Cheng CY, Chen YJ, Huang TJ, Wei Hsu RW (1996) Treatment of the femoral neck and trochanteric benign lesions. Clin Orthop Relat Res 328, 220–226.
2. George B, Abudu A, Grimer RJ, Carter SR, Tillman RM (2008) The treatment of benign lesions of the proximal femur with non-vascularised autologous fibular strut grafts. J Bone Joint Surg 90-B, 648–651.
3. Jaffe KA, Launer EP, Scholl BM (2002) Use of fibular allograft strut in the treatment of benign lesions of the proximal femur. Am J Orthop 31, 575–578.
4. Jaffe KA, Dunham WK (1990) Treatment of benign lesions of the femoral head and neck. Clin Orthop 257, 134–137.
5. Enneking WF, Gearen PF (1986) Fibrous dysplasia of the femoral neck; treatment by cortical bone grafting. J Bone Joint Surg Am 68, 1415–1422.
6. Gunther KP, Hartmann A, Aikele P, Aust D, Ziegler J (2007) Large femoral-neck cysts in association with femoracetabular impingement: a report of three cases. J Bone Joint Surg Am 89, 863–870.
7. Tomford WW, Mankin HJ (1999) Bone banking: update on methods and materials. Clin Orthop North Am 30(4), 565–570.
8. Tomford WW (1995) Transmission of disease through transplantation of musculoskeletal allografts. J Bone Joint Surg Am 77-A, 1742–1754.
9. Mankin HJ, Gebhardt MC, Jennings LC, Springfield DS, Tomford WW (1996) Long-term results of allograft replacement in the management of bone tumors. Clin Orthop 324, 86–97.
10. Matsumine A, Myoui A, Kusuzaki K et al. (2004) Calcium hydroxyapatite ceramic implants in bone tumour surgery. A long-term follow-up study. J Bone Joint Surg Br 86, 719–725.
11. Matsumine A, Kusuzaki K, Matsubara T et al. (2006) Calcium phosphate cement in musculoskeletal tumor surgery. J Surg Oncol 93, 212–220.
12. Welch RD, Zhang H, Bronson DG (2003) Experimental tibial plateau fractures augmented with calcium phosphate cement or autologous bone graft. J Bone Joint Surg Am 85-A, 222–231.
13. Larsson S, Bauer TW (2002) Use of injectable calcium phosphate cement for fracture fixation: a review. Clin Orthop 395, 23–32.
14. Hu YC, Lun DX, Zhao SK (2012) Combined anterior and lateral approaches for bone tumors of the femoral neck and head. Orthopedics 35, e628–634.